



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/52, 47/10</b>		A1	(11) International Publication Number: <b>WO 97/34607</b>
			(43) International Publication Date: 25 September 1997 (25.09.97)
(21) International Application Number: PCT/GB97/00779 (22) International Filing Date: 20 March 1997 (20.03.97) (30) Priority Data: 9605859.9      20 March 1996 (20.03.96)      GB 9618975.8      11 September 1996 (11.09.96)      GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED (GB/GB); Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): LUDWIG, John [US/US]; 432 Capital Lane, Gurnee, IL 60031 (US). (74) Agent: SKAILES, Humphrey, John; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
(54) Title: TOPICAL FORMULATIONS OF ACICLOVIR			
(57) Abstract			
An oil-in-water topical pharmaceutical formulation comprising aciclovir or a salt or an ester thereof, water and at least 10 % diethylene glycol monoethyl ether, and its use in the treatment or prevention of infections caused by Herpes zoster, Herpes varicella and Herpes simplex types 1 and 2.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

TOPICAL FORMULATIONS OF ACICLOVIR

This invention relates to a topical pharmaceutical formulation suitable for use in treating virus infections of the skin and mucosa, and in particular it relates to topical formulations containing 9-(2-hydroxyethoxymethyl)guanine, otherwise known as aciclovir, and hereinafter referred to as such.

Aciclovir and pharmaceutically acceptable salts and esters thereof are known to have antiviral activity against various classes of DNA and RNA viruses both *in vitro* and *in vivo*, see UK patent No. 1 523 865. In particular the compound is active against herpes simplex virus which causes herpetic keratitis in rabbits, herpetic encephalitis in mice, and cutaneous herpes in guinea pigs and mice. Aciclovir has been found to be effective in the treatment of herpes simplex virus and herpes zoster virus in humans.

Aciclovir suffers from the disadvantage that it has a low solubility in water and is almost totally insoluble in hydrophobic solvent systems. It is accordingly difficult to produce a topical formulation containing a sufficient dissolved concentration of active ingredient for it to exert its full effect and also to optimise the flux of the compound into the skin. In addition to ease of release it is also important that any formulation of a pharmaceutically active compound should be stable for long periods of time, should not lose its potency, should not discolour or form insoluble substances or complexes, and also should not be unduly irritating to the skin or mucosa.

European Patent No. 0 044 543 describes oil-in-water topical pharmaceutical formulations of aciclovir wherein the aqueous phase contains at least 30% of a water miscible polyhydric alcohol,

We have now found that oil-in-water topical pharmaceutical formulations of aciclovir comprising at least 10% by weight of diethylene glycol monoethyl ether have particularly advantageous properties. In particular, such formulations exhibit enhanced efficacy together with low irritancy and good physical stability.

- 2 -

The present invention accordingly provides a topical pharmaceutical formulation comprising water, aciclovir and at least 10% w/w of diethylene glycol monoethyl ether by weight of the formulation.

5 Preferably the formulation of the invention contains a maximum of 50% water.

Such a topical formulation may contain 0.075% to 10% w/w aciclovir or a salt or an ester thereof, from 10% to 50% w/w of diethylene glycol monoethyl ether, from 15% to 50% w/w water and an oil phase. Hereafter references to aciclovir  
10 should be understood to include also its pharmaceutically acceptable salts and esters unless the context clearly indicates otherwise.

In a preferred aspect the formulation comprises from 0.5% to 10% w/w aciclovir, from 20% to 40% w/w of diethylene glycol monoethyl ether, from 20% to 40%  
15 w/w water together with an oil phase, whilst the most preferred formulation comprises from 1% to 5% w/w aciclovir, from 30% to 40% w/w of diethylene glycol monoethyl ether, from 25% to 40% w/w water together with an oil phase.

Diethylene glycol monoethyl ether is manufactured by Gatttefossé S.A., 36  
20 Chemin de Genas, b.p. 603, 69804 Saint-Priest Cedex, France, under the tradename TRANSCUTOL™.

The oil phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an  
25 emulsifier (otherwise known as an emulgent), it is desirably comprised of a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, as explained in more detail below, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred  
30 to include both an oil and a fat. Together, the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so called emulsifying ointment base which forms the oil dispersed phase of the emulsions.

Emulgents and emulsion stabilisers suitable for use in the formulation of the  
35 present invention include cetyl alcohol, sodium lauryl sulphate, stearyl alcohol

and polyoxyethylene alkyl ethers, such as brij 721 and brij 72 and polyoxyl stearyl ethers, for example steareth 2 and steareth 21.

The formulations of the invention may also comprise additional components in the aqueous phase, for example polyhydric alcohols such as propylene glycol. Preferably the formulations of the invention comprise from 0 to 30% by weight of propylene glycol.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of aciclovir in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dialkyl esters such as diisopropyl adipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a mixed ester of 2-ethyl hexanoic acid with a blend of cetyl or stearyl alcohols known as Crodamol CAP may be used, the last three being the preferred esters. These may be used singly or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

A preferred formulation according to the invention comprises diethylene glycol monoethyl ether, 30-40% w/w; aciclovir, approximately 5% w/w; cetyl alcohol 3-10% w/w; stearyl alcohol, 4-10% w/w; propylene glycol, 0-10% w/w; light mineral oil, 8-15% w/w; steareth 21 or brij 721, 2-5% w/w; steareth 2 or brij 72, 1-3% w/w; and purified water to 100% w/w.

The formulations of the invention may, if desired, include one or more pharmaceutically acceptable preservatives. However, we have found that the use of preservatives is not essential in the formulations of the invention, which finding represents an advantage of the said formulations.

The present invention further provides a method for the preparation of a topical pharmaceutical formulation, as hereinbefore defined, which comprises mixing

- 4 -

the combination of aciclovir, diethylene glycol monoethyl ether and water with the oil phase.

5 The manner of formulating the emulsion will of course vary according to the amount and nature of the constituents, but nevertheless follows known techniques in emulsion technology (see the Pharmaceutical Codex, London, the Pharmaceutical Press, 1979). For example the aciclovir may be initially incorporated wholly in the aqueous portion where it may form a solution alone, or a mixed solution/suspension, and then emulsified with the ointment base.

10 Alternatively where high concentrations of aciclovir are being used, a part of the aqueous portion may be formulated as an emulsion, and the balance of the water, diethylene glycol monoethyl ether and aciclovir added to and dispersed into the emulsion. In another technique the aciclovir may be included in the emulsifying ointment prior to emulsification with the aqueous portion. In using

15 these procedures, it is preferable to heat the aqueous portion and the ointment base to about 40 to 80°C, preferably 50 to 70°C, prior to emulsification which may be achieved by vigorous agitation using for example a standard laboratory mixer. Finer dispersions of the oil phase may be obtained by homogenising or milling in a colloidal mill.

20 A topical formulation of the present invention may be used in the treatment or prevention of viral infections caused for example by Herpes zoster, Herpes varicella and Herpes simplex types 1 and 2, which cause diseases such as shingles, chicken pox, cold sores and genital herpes. The formulation should

25 desirably be applied to the affected area of skin from 1 to 6 times daily, preferably from 3 to 5 times.

The following examples illustrate the invention and are not intended as a limitation thereof.

30

Example 1

	Ingredient	% w/w
	TRANSCUTOL™	40.0
5	aciclovir	5.0
	stearyl alcohol	5.0
	cetyl alcohol	4.0
	light mineral oil	10.2
	brij 721	2.5
10	brij 72	2.3
	Purified water	to 100

The oil phase comprising stearyl alcohol, cetyl alcohol, light mineral oil, brij 72 and brij 721 is heated to 70-75°C with mixing. Purified water is heated to 65-70°C and added to the oil phase, maintaining the temperature at 70-75°C, with mixing to form an emulsion. The mixture is maintained at a temperature of 70-75°C for approximately 5 minutes. TRANSCUTOL™ is weighed into an appropriate container and aciclovir added with mixing to form a suspension. The aciclovir suspension is added to the emulsion, rinsing in with a small amount of purified water. The emulsion is homogenized for approximately 5 minutes, then made up to final batch weight with purified water. The resulting cream is cooled to ambient temperature (approximately 30°C) with continuous mixing and filled into suitable tubes which are then sealed.

Example 2

	Ingredient	% w/w
	TRANSCUTOL™	30.0
	aciclovir	5.0
	stearyl alcohol	5.0
30	cetyl alcohol	4.0
	light mineral oil	10.2
	brij 721	2.5
	brij 72	2.3
	propylene glycol	10.0
35	Purified water	to 100

The oil phase comprising stearyl alcohol, cetyl alcohol, light mineral oil, brij 72 and brij 721 is heated to 70-75°C with mixing. Purified water is heated to 70-75°C and added to the oil phase, maintaining the temperature at 70-75°C, with mixing to form an emulsion. The mixture is maintained at a temperature of 70-75°C for approximately 5 minutes. TRANSCUTOL™ is weighed into an appropriate container and propylene glycol and aciclovir added with mixing to form a suspension which is homogenized at 65-70°C for approximately 5 minutes. The propylene aciclovir suspension is added to the emulsion at 50-70°C, suitably 50-55°C, rinsing in with a small amount of purified water. The emulsion is homogenized for approximately 5 minutes, then made up to final batch weight with purified water. The resulting cream is cooled to ambient temperature (approximately 30°C) with continuous mixing and filled into suitable tubes which are then sealed.

### Example 3

The formulations described in Examples 1 and 2 may alternatively be prepared by the following modified procedure.

The oil phase is weighed and heated to 70-75°C with continuous slow mixing. Purified water is heated to 65-70°C. The purified water is added with propeller agitation to the suspension of aciclovir in TRANSCUTOL™. The resulting aqueous mixture is heated to 65-70°C. Whilst maintaining the temperature of the oil phase at 70-75°C, the aqueous phase is slowly added with sweep agitation for at least 5 minutes. The aqueous phase container is rinsed with purified water and the rinsings added to the main batch. The temperature of the batch is maintained at 70-75°C and the batch is homogenized for at least 5 minutes. The batch is cooled to 30-35°C with continuous sweep agitation and purified water added to adjust to final batch weight. The batch is mixed until uniform and cooled to 30°C.



Example 4      Experimental DataHerpes Simplex Virus Animal Data: Mouse Snout Model

5

METHODS: Female HRS/J mice were infected cutaneously with wild-type HSV-1. After the mice were anaesthetised with ketamine and xylazine, the skin of the snout region was lightly abraded with a Dremel® roto-tool. Groups of ten mice were then inoculated on the skin of the snout from an SC-16 HSV stock solution diluted to a final concentration of 1 E6 PFU/ml. The abrasion area was then swabbed for ten seconds with a sterile cotton swab soaked with the viral stock.

10

15 TREATMENT: Mice were treated for five days starting three days post-innoculation (PI) and continues through day eight. Mice were treated topically twice daily at 0800 and 1400 hours.

TREATMENT 1. No treatment (N=15)

20

GROUPS: 2. 5% Aciclovir in formulation A (N = 30)

3. 5% Aciclovir in formulation B (N = 30)

OUTCOME Lesions were scored at the same time each day. During dosing

ASSESSMENT: period lesion scores were assessed prior to the first treatment application in the morning. The scoring system is outlined below:

25

0 = Normal skin

+1 = 1 to 5 discrete lesions

+2 = ≥ 6 discrete lesions

+3 = confluent lesions

+4 = necrotic lesions or death

30

35

STATISTICAL: The lesions are graphed and the average area under the curve  
ANALYSIS (AUC) is calculated to compare compound efficacies.  
Statistical analysis of data is performed using the unpaired t-test  
assuming equal variances (Microsoft® Excel program, version  
4.0).

Formulation A: 5% w/w aciclovir  
40% diethylene glycol monoethyl ether  
4% cetyl alcohol  
5% stearyl alcohol  
10.2% light mineral oil  
2.3% brij 72  
2.5% brij 721  
31% water

Formulation B: 5% w/w aciclovir  
30% diethylene glycol monoethyl ether  
10% propylene glycol  
4% cetyl alcohol  
5% stearyl alcohol  
10.2% light mineral oil  
2.3% brij 72  
2.5% brij 721  
31% water

- 9 -

ResultsDay PI/Average Lesion Score

5

Treatment Group	1	2	3	4	5	6	7	8	Area Under the Curve (AUC)
1	0.0	0.0	0.0	0.1	2.1	3.3	3.9	4.0	11.4
2	0.0	0.0	0.1	0.1	0.3	0.9	1.5	2.0	3.9
3	0.0	0.0	0.0	0.1	0.9	1.5	2.7	3.2	6.8

Pairwise Treatment Comparisons t-Value<sup>1</sup>  
(P < 0.05)

10	No treatment 1 vs. treatment 2	***
	No treatment 1 vs. treatment 3	***
	Treatment 2 vs. treatment 3	***

<sup>1</sup> Alpha = 0.05, Confidence 0.05, Critical Value of T = 2.706

15 \*\*\* - Statistically significant difference between paired treatments

Claims

1. A topical pharmaceutical formulation comprising water, aciclovir or a pharmaceutically acceptable salt or ester thereof and at least 10% w/w diethylene glycol monoethyl ether.
2. A formulation as claimed in claim 1 comprising 0.075% to 10% w/w aciclovir or a pharmaceutically acceptable salt or ester thereof, 10% to 50% w/w of diethylene glycol monoethyl ether, from 15% to 50% w/w water and an oil phase.
3. A formulation as claimed in claim 1 comprising 0.5% to 10% w/w aciclovir or a pharmaceutically acceptable salt or ester thereof, 20% to 40% w/w of diethylene glycol monoethyl ether, 20% to 40% w/w water together with an oil phase.
4. A formulation as claimed in claim 1 comprising 1% to 5% aciclovir or a pharmaceutically acceptable salt or ester thereof, 30% to 40% w/w diethylene glycol monoethyl ether, 25% to 40% w/w water together with an oil phase.
5. A formulation as claimed in any of claims 2 to 4, wherein the oil phase comprises at least one hydrophilic emulsifier and at least one lipophilic emulsifier, together with at least one fat and/or oil.
6. A formulation as claimed in any preceding claim, which contains at least one emulsifier selected from cetyl alcohol, sodium lauryl sulphate, stearyl alcohol and a polyoxyethylene alkyl ether.

- 11 -

7. A formulation as claimed in any preceding claim, further comprising at least one polyhydric alcohol in the aqueous phase.

8. A formulation as claimed in claim 1 which comprises 30-40% w/w diethylene glycol monoethyl ether, approximately 5% w/w aciclovir, 3-10% w/w cetyl alcohol, 4-10% w/w stearyl alcohol, 0-10% w/w propylene glycol, 8-15% w/w light mineral oil, 2-5% w/w steareth 21 or brij 721, 1-3% w/w steareth 2 or brij 72, and purified water to 100% w/w.

9. A process for the preparation of a topical pharmaceutical formulation as claimed in any of the preceding claims comprising mixing the combination of aciclovir or a pharmaceutically acceptable salt or ester thereof, diethylene glycol monoethyl ether and water with the oil phase.

10. A method of treatment and/or prevention of infections in humans or animals caused by Herpes zoster, Herpes varicella and Herpes simplex types 1 and 2 comprising administering to the subject an effective amount of a formulation as claimed in any of claims 1 to 8.

## INTERNATIONAL SEARCH REPORT

Int. Appl. No.

PCT/GB 97/00779

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/52 A61K47/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 15614 A (AGIS IND 1983 LIMITED ;GODWIN EDGAR JAMES (GB)) 21 July 1994 see page 7 ---	1
Y	EP 0 044 543 A (WELLCOME FOUND) 27 January 1982 cited in the application see page 2, line 8 - line 21; claims 1-12 ---	1-10
Y	WO 95 35095 A (YISSUM RES DEV CO ;TOUITOU ELKA (IL)) 28 December 1995 see page 12; example VII see claims 1-9 ---	1-10
Y	WO 90 11064 A (CYGNUS RESEARCH CORP) 4 October 1990 see page 3, line 5 - line 6 ---	1-10

-/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is examined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

1

Date of the actual completion of the international search

22 May 1997

Date of mailing of the international search report

27 June 1997 (27.06.97)

Name and mailing address of the ISA

European Patent Office, P. B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Seegert, K

# INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/GB 97/00779

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PATENT ABSTRACTS OF JAPAN  vol. 015, no. 231 (C-0840), 12 June 1991  &amp; JP 03 072426 A (TEIKOKU SEIYAKU KK), 27  March 1991,  see abstract</p> <p style="text-align: center;">-----</p>	1-10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/00779

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9415614 A	21-07-94	IL 104283 A	05-12-96
		AU 671704 B	05-09-96
		AU 5711894 A	15-08-94
		CA 2152907 A	21-07-94
		EP 0677126 A	18-10-95
		JP 8505850 T	25-06-96
		US 5585379 A	17-12-96
-----			
EP 0044543 A	27-01-82	GB 2080106 A,B	03-02-82
		AR 225680 A	15-04-82
		AU 547391 B	17-10-85
		AU 7307381 A	21-01-82
		BG 60450 B	28-04-95
		CA 1172169 A	07-08-84
		CY 1309 A	06-12-85
		HK 95485 A	06-12-85
		JP 1048885 B	20-10-89
		JP 1563405 C	12-06-90
		JP 57042615 A	10-03-82
		KE 3561 A	01-11-85
		SU 1375113 A	15-02-88
		US 4963555 A	16-10-90
-----			
WO 9535095 A	28-12-95	US 5540934 A	30-07-96
		AU 2977695 A	15-01-96
-----			
WO 9011064 A	04-10-90	US 4973468 A	27-11-90
		AU 629331 B	01-10-92
		AU 5417490 A	22-10-90
		CA 2012875 A,C	22-09-90
		EP 0464150 A	08-01-92
		JP 2550441 B	06-11-96
		JP 4505157 T	10-09-92
		KR 9510324 B	14-09-95
		US 5053227 A	01-10-91
		US 5059426 A	22-10-91
-----			